- American City Business Journals•4 days ago
Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals on Jan. 9 valued the Cambridge cancer drug firm at $24 per share, a 75 percent premium over its previous closing stock price. A federal filing by Ariad (ARIA) on Thursday includes a lengthy play-by-play of the negotiations, beginning with a phone call on Dec. 2 between Ariad CEO Paris Panayiotopoulos and Takeda CEO Christophe Weber. During the call, Panayiotopoulos told Weber that if Takeda was interested in making a “broader” deal, it should do so in writing, according to the filing.
- Financial Times•6 days ago
Takeda, Japan's largest drugmaker, has outsourced the development of a drug for rare forms of childhood epilepsy to a US biotech company in an unusual deal that underscores the growing importance of smaller ...
- Zacks•13 days ago
Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.
TKPYY : Summary for TAKEDA PHARMA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||20.46 - 20.96|
|52 Week Range||19.96 - 25.40|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.81|
|Dividend & Yield||0.78 (3.80%)|
|1y Target Est||N/A|